BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 255 filers reported holding BLUEBIRD BIO INC in Q4 2018. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $698,646 | -54.1% | 219,700 | -0.1% | 0.00% | -50.0% |
| Q4 2022 | $1,521,438 | -60.7% | 219,861 | -64.1% | 0.00% | -63.6% |
| Q3 2022 | $3,876,000 | -19.1% | 612,375 | -47.1% | 0.01% | -15.4% |
| Q2 2022 | $4,791,000 | +7.8% | 1,157,322 | +26.2% | 0.01% | +30.0% |
| Q1 2022 | $4,446,000 | +71.2% | 916,803 | +252.6% | 0.01% | +100.0% |
| Q4 2021 | $2,597,000 | -21.3% | 259,998 | +50.6% | 0.01% | -16.7% |
| Q3 2021 | $3,298,000 | +358.1% | 172,605 | +936.8% | 0.01% | +500.0% |
| Q4 2020 | $720,000 | +36.4% | 16,648 | +70.3% | 0.00% | 0.0% |
| Q3 2020 | $528,000 | -14.6% | 9,778 | -3.5% | 0.00% | -50.0% |
| Q2 2020 | $618,000 | -15.3% | 10,129 | +102.6% | 0.00% | 0.0% |
| Q3 2018 | $730,000 | +55.0% | 5,000 | +66.7% | 0.00% | +100.0% |
| Q2 2018 | $471,000 | -65.5% | 3,000 | -62.5% | 0.00% | -75.0% |
| Q1 2018 | $1,366,000 | -76.2% | 8,000 | -75.2% | 0.00% | -75.0% |
| Q4 2017 | $5,743,000 | +127.6% | 32,247 | +75.5% | 0.02% | +128.6% |
| Q3 2017 | $2,523,000 | +34.6% | 18,371 | +2.9% | 0.01% | +40.0% |
| Q2 2017 | $1,875,000 | -23.3% | 17,854 | -33.6% | 0.01% | -28.6% |
| Q1 2017 | $2,443,000 | +32.0% | 26,875 | -10.4% | 0.01% | +16.7% |
| Q4 2016 | $1,851,000 | +127.7% | 30,000 | +150.0% | 0.01% | +200.0% |
| Q3 2016 | $813,000 | -40.5% | 12,000 | -62.0% | 0.00% | -50.0% |
| Q2 2016 | $1,367,000 | +60.8% | 31,562 | +57.8% | 0.00% | +33.3% |
| Q1 2016 | $850,000 | +65.4% | 20,000 | +150.0% | 0.00% | +50.0% |
| Q4 2015 | $514,000 | -24.9% | 8,000 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $684,000 | -49.2% | 8,000 | 0.0% | 0.00% | -50.0% |
| Q2 2015 | $1,347,000 | +39.4% | 8,000 | 0.0% | 0.00% | +33.3% |
| Q1 2015 | $966,000 | – | 8,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
| Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
| PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
| Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
| Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
| Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
| Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
| Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
| Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
| Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |